Metronomic and metronomic-like therapies in neuroendocrine tumors – Rationale and clinical perspectives
Authors:
- 1 April 2017
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 55, 46-56
Abstract
No abstract availableKeywords
This publication has 75 references indexed in Scilit:
- Metronomic anti-cancer therapy – an ongoing treatment option for advanced cancer patientsjournal of Cancer Therapeutics and Research, 2012
- Metronomic chemotherapy: new rationale for new directionsNature Reviews Clinical Oncology, 2010
- Adaptive TherapyCancer Research, 2009
- Metronomic Chemotherapy: Changing the Paradigm That More Is BetterCurrent Oncology, 2009
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- Evolution of the Diffuse Neuroendocrine System – Clear Cells and Cloudy OriginsNeuroendocrinology, 2006
- Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumorsGastroenterology, 2003
- Chemotherapeutic drugs—more really is not betterNature Medicine, 2000
- Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in miceJournal of Clinical Investigation, 2000
- Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agentsBioEssays, 1991